Schmidt P J Investment Management Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,656 shares of the company’s stock after selling 509 shares during the period. Johnson & Johnson accounts for 2.6% of Schmidt P J Investment Management Inc.’s portfolio, making the stock its 4th biggest holding. Schmidt P J Investment Management Inc.’s holdings in Johnson & Johnson were worth $8,421,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. Lau Associates LLC lifted its position in shares of Johnson & Johnson by 12.8% during the 1st quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock valued at $5,839,000 after buying an additional 5,335 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in Johnson & Johnson by 7.3% during the 4th quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock valued at $1,627,000 after purchasing an additional 957 shares during the period. Burke & Herbert Bank & Trust Co. raised its stake in Johnson & Johnson by 2.6% during the 1st quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock valued at $5,895,000 after purchasing an additional 1,218 shares during the period. Paradigm Financial Advisors LLC raised its stake in Johnson & Johnson by 17.1% during the 1st quarter. Paradigm Financial Advisors LLC now owns 2,640 shares of the company’s stock valued at $328,000 after purchasing an additional 386 shares during the period. Finally, Oakbrook Investments LLC raised its stake in Johnson & Johnson by 7.4% during the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after purchasing an additional 9,375 shares during the period. 66.00% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages recently issued reports on JNJ. UBS AG reissued a “buy” rating and set a $136.00 target price on shares of Johnson & Johnson in a research note on Monday, May 15th. J P Morgan Chase & Co lifted their target price on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research note on Wednesday, August 16th. Cowen and Company set a $147.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, August 24th. Jefferies Group LLC set a $145.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research note on Tuesday, August 15th. Finally, Wells Fargo & Company reissued a “market perform” rating and set a $135.00 target price (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $134.60.
In related news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Stake Decreased by Schmidt P J Investment Management Inc.” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/09/10/johnson-johnson-jnj-stake-decreased-by-schmidt-p-j-investment-management-inc.html.
Johnson & Johnson (NYSE JNJ) traded down 0.92% during trading on Friday, hitting $130.98. The stock had a trading volume of 4,854,414 shares. The company’s 50 day moving average is $132.48 and its 200-day moving average is $128.74. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The company has a market cap of $351.55 billion, a PE ratio of 22.16 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the firm earned $1.74 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.